


**Product Name** : Parsaclisib  
**Cat. No.** : PC-60527  
**CAS No.** : 1426698-88-5  
**Molecular Formula** : C<sub>20</sub>H<sub>22</sub>ClFN<sub>6</sub>O<sub>2</sub>  
**Molecular Weight** : 432.88  
**Target** : PI3K  
**Solubility** : >200 mM in DMSO (>86 mg/mL)

1. Shin N, et al. *J Pharmacol Exp Ther.* 2020 Jul;374(1):211-222.



## Biological Activity

Parsaclisib (INCB050465) is a potent and highly selective **PI3Kδ** inhibitor with IC<sub>50</sub> of < 1 nM (SPA).

Parsaclisib (INCB050465) displayed cellular activity in SU-DHL-6 viability (IC<sub>50</sub>=1.6 nM) and Pfeiffer proliferation (IC<sub>50</sub>=2.5 nM).

Parsaclisib (INCB050465) is very selective over the other PI3K isoforms (PI3Kα/β/γ FB IC<sub>50</sub> values >10,000 nM), exhibits selectivity over a panel of 197 kinases and is very potent in the RAMOS cellular and human whole blood basophil assays. Parsaclisib (INCB050465) dosed orally twice daily significantly inhibited Pfeiffer xenograft tumor growth at 1 mg/kg, with profound inhibition of the phosphorylation of AKT at Ser473, a marker of PI3Kδ activity, observed in mice models. Parsaclisib (INCB050465) directly blocks PI3K signaling-mediated cell proliferation in B-cell lines in vitro and in vivo and indirectly controls tumor growth by lessening immunosuppression through regulatory T-cell inhibition in a syngeneic lymphoma model.

## References

- Forero-Torres A, et al. *Blood.* 2019 Apr 18;133(16):1742-1752.
- Yue EW, et al. *ACS Med Chem Lett.* 2019 Oct 17;10(11):1554-1560.

